Exco Intouch has announced that its electronic patient reported outcomes (Epro) solution has been selected by Synairgen.
Exco Intouch's SMS Epro will enable Synairgen to collect patient data in its second clinical study of inhaled interferon beta (IFN-beta) for asthma treatment.
This phase one study from Synairgen is designed to establish the safety of inhaled IFN-beta at four different dose levels over a 14-day period in asthmatic volunteers.
Epro will enable Synairgen to collect accurate PRO data which might be crucial in gauging the efficacy in future studies.
Using secure mobile online access, the technology will allow patients to complete diary questionnaires at pre-specified times via a series of text messages.
Secure text messages will enable Synairgen's patients to record and transmit data concerning their asthma using their own mobile phone, facilitating diary data collection which is then relayed back to the clinical sites for further analyses.